Clinical Trial Update: Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC [Phase 2]

View source ↗

Summary

Phase II results have been posted for a nivolumab-ipilimumab-taxane regimen in untreated metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Taxane-based chemotherapy (unspecified) (taxane)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Jeffrey Clarke | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-10-14